Liver cancer remains a global health challenge, with an estimated incidence of> 1 million
cases by 2025. Hepatocellular carcinoma (HCC) is the most common form of liver cancer …

Historically, studies of disseminated tumour cells in bone marrow and circulating tumour
cells in peripheral blood have provided crucial insights into cancer biology and the …

Precision oncology seeks to leverage molecular information about cancer to improve patient
outcomes. Tissue biopsy samples are widely used to characterize tumours but are limited by …

Summary Background Circulating tumour DNA (ctDNA) testing might provide a current
assessment of the genomic profile of advanced cancer, without the need to repeat tumour …

Emerging Roles of Cell-free Tumor DNA in Oncology The capacity to detect new cancers,
treatment-resistant variants, and tumor heterogeneity by noninvasive technology on the …

Circulating tumor DNA (ctDNA) sequencing is being rapidly adopted in precision oncology,
but the accuracy, sensitivity and reproducibility of ctDNA assays is poorly understood. Here …

Liquid biopsies, comprising the noninvasive analysis of circulating tumor-derived material
(the 'tumor circulome'), represent an innovative tool in precision oncology to overcome …

Importance Tumor mutational burden (TMB), as measured by whole-exome sequencing
(WES) or a cancer gene panel (CGP), is associated with immunotherapy responses …

Abstract Purpose The therascreen PIK3CA mutation assay and the alpha-specific PI3K
inhibitor alpelisib are FDA-approved for identifying and treating patients with advanced …

The genomics of primary prostate cancer differ from those of metastatic castration-resistant
prostate cancer (mCRPC). We studied genomic aberrations in primary prostate cancer …